Oppenheimer Asset Management
TSHA icon

Oppenheimer Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Oppenheimer Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,773
Closed -$59.3K – 1177
2025
Q4 		$59.3K Buy
+10,773
New +$52.3K ﹤0.01% 1062

Other funds holding TSHA

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Oppenheimer Asset Management's TSHA Position: Q1 2026 in Review

Oppenheimer Asset Management sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 10,773 shares — an estimated $59.3K sold.

Oppenheimer Asset Management first reported a position in TSHA in Q4 2025 and held it in 1 quarter. The position peaked at $59.3K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Oppenheimer Asset Management reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Oppenheimer Asset Management sold 10,773 Taysha Gene Therapies shares in Q1 2026, an estimated $59.3K.
  • Oppenheimer Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 1 quarter.
  • Oppenheimer Asset Management's Taysha Gene Therapies position peaked at $59.3K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.